Using PET/CT imaging to diagnose GLP-1 receptor related diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effectiveness of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in patients with GLP-1 receptor-related diseases. Participants include adults with suspected or newly diagnosed malignant tumors who are scheduled for an Exendin 4 PET/CT scan. The study measures the uptake of lesions using the maximum standard uptake value (SUVmax) and calculates various diagnostic metrics such as sensitivity and specificity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Where it's running

• The First Affiliated Hospital of University of Science and Technology of China
  Hefei, Anhui, China Recruiting
• The Affiliated Hospital of Qingdao University
  Qingdao, Shandong, China Recruiting
• Tianjin Medical University General Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Qiusong Chen, MD
• Email: qs_c8@hotmail.com
• Phone: +862260362190

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A new PET/CT test to find insulinoma using a GLP-1R tracer compared to an earlier tracer

  A GLP-1 receptor–targeted PET/CT imaging agent is being tested in adults with suspected or confirmed insulinoma to see if the PEG6-modified tracer locates tumors better than the original tracer.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07808879

• PD-L1 PET/CT to see primary and metastatic PD-L1-related lesions in adults

  This study tests whether 68Ga/18F-PD-L1 PET/CT can help detect primary and metastatic PD-L1-related tumors in adults.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07618936

• EUS-guided radiofrequency ablation for pancreatic insulinoma safety and effectiveness

  This project will try EUS-guided radiofrequency ablation (EUS-RFA) to treat people with pathology-confirmed pancreatic insulinoma and compare safety and outcomes to historic surgical patients.

  Recruiting Sahlgrenska University Hospital · Gothenburg · NCT07585032

• Endoscopic ultrasound-guided radiofrequency ablation for pancreatic and left adrenal lesions

  This will try EUS-guided radiofrequency ablation to control symptoms and hormone-related problems in adults with small pancreatic neuroendocrine tumors (including insulinomas) or certain left adrenal adenomas.

  Recruiting Herlev Hospital · Herlev, Capital Region · NCT07272187

• FAPI-PET/CT imaging for diagnosing and staging pancreatic cancer

  This study will try 18F‑FAPI‑74 PET/CT scans in adults with suspected or recurrent pancreatic cancer to see if they detect lymph node spread and distant metastases more accurately.

  Recruiting Phase 2/3 Turku University Hospital · Turku · NCT07098598

• Longer fasting to reduce stomach contents for people on GLP‑1 medications having upper endoscopy

  This project will test whether a longer fasting period before upper endoscopy reduces stomach contents in people taking GLP‑1 receptor agonist medications.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07006142

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.